Alemtuzumab in refractory Sézary syndrome

Detalhes bibliográficos
Autor(a) principal: Reifs,Carmen María Alcántara
Data de Publicação: 2016
Outros Autores: Salido-Vallejo,Rafael, Garnacho-Saucedo,Gloria María, Corte-Sánchez,Sofía De la, González-Menchen,Alberto, García-Nieto,Antonio Vélez
Tipo de documento: Relatório
Idioma: eng
Título da fonte: Anais brasileiros de dermatologia (Online)
Texto Completo: http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0365-05962016000500642
Resumo: Abstract: Sézary syndrome is a primary cutaneous T-cell lymphoma characterized by the triad of erythroderma, lymphadenopathy and circulating atypical cells. The emergence of new molecular targets has enabled the development of drugs such as alemtuzumab, an anti-CD52 monoclonal antibody, which has shown promising results in the treatment of this entity. We report the case of a 70-year-old male with refractory Sézary syndrome in whom treatment with alemtuzumab achieved an 80% skin lesion clearance with complete haematologic and radiologic response. The treatment was discontinued after 4 months due to adverse effects, with the patient showing a sustained response without disease progression after 13 months of follow-up.
id SBD-1_6a2a96414107470d632a38a8adfddeec
oai_identifier_str oai:scielo:S0365-05962016000500642
network_acronym_str SBD-1
network_name_str Anais brasileiros de dermatologia (Online)
repository_id_str
spelling Alemtuzumab in refractory Sézary syndromeAntibodies, monoclonal, humanizedLymphoma, T-Cell, cutaneousSézary syndromeTreatment outcomeAbstract: Sézary syndrome is a primary cutaneous T-cell lymphoma characterized by the triad of erythroderma, lymphadenopathy and circulating atypical cells. The emergence of new molecular targets has enabled the development of drugs such as alemtuzumab, an anti-CD52 monoclonal antibody, which has shown promising results in the treatment of this entity. We report the case of a 70-year-old male with refractory Sézary syndrome in whom treatment with alemtuzumab achieved an 80% skin lesion clearance with complete haematologic and radiologic response. The treatment was discontinued after 4 months due to adverse effects, with the patient showing a sustained response without disease progression after 13 months of follow-up.Sociedade Brasileira de Dermatologia2016-10-01info:eu-repo/semantics/reportinfo:eu-repo/semantics/publishedVersiontext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S0365-05962016000500642Anais Brasileiros de Dermatologia v.91 n.5 2016reponame:Anais brasileiros de dermatologia (Online)instname:Sociedade Brasileira de Dermatologia (SBD)instacron:SBD10.1590/abd1806-4841.20164322info:eu-repo/semantics/openAccessReifs,Carmen María AlcántaraSalido-Vallejo,RafaelGarnacho-Saucedo,Gloria MaríaCorte-Sánchez,Sofía De laGonzález-Menchen,AlbertoGarcía-Nieto,Antonio Vélezeng2016-11-04T00:00:00Zoai:scielo:S0365-05962016000500642Revistahttp://www.anaisdedermatologia.org.br/https://old.scielo.br/oai/scielo-oai.phpabd@sbd.org.br||revista@sbd.org.br1806-48410365-0596opendoar:2016-11-04T00:00Anais brasileiros de dermatologia (Online) - Sociedade Brasileira de Dermatologia (SBD)false
dc.title.none.fl_str_mv Alemtuzumab in refractory Sézary syndrome
title Alemtuzumab in refractory Sézary syndrome
spellingShingle Alemtuzumab in refractory Sézary syndrome
Reifs,Carmen María Alcántara
Antibodies, monoclonal, humanized
Lymphoma, T-Cell, cutaneous
Sézary syndrome
Treatment outcome
title_short Alemtuzumab in refractory Sézary syndrome
title_full Alemtuzumab in refractory Sézary syndrome
title_fullStr Alemtuzumab in refractory Sézary syndrome
title_full_unstemmed Alemtuzumab in refractory Sézary syndrome
title_sort Alemtuzumab in refractory Sézary syndrome
author Reifs,Carmen María Alcántara
author_facet Reifs,Carmen María Alcántara
Salido-Vallejo,Rafael
Garnacho-Saucedo,Gloria María
Corte-Sánchez,Sofía De la
González-Menchen,Alberto
García-Nieto,Antonio Vélez
author_role author
author2 Salido-Vallejo,Rafael
Garnacho-Saucedo,Gloria María
Corte-Sánchez,Sofía De la
González-Menchen,Alberto
García-Nieto,Antonio Vélez
author2_role author
author
author
author
author
dc.contributor.author.fl_str_mv Reifs,Carmen María Alcántara
Salido-Vallejo,Rafael
Garnacho-Saucedo,Gloria María
Corte-Sánchez,Sofía De la
González-Menchen,Alberto
García-Nieto,Antonio Vélez
dc.subject.por.fl_str_mv Antibodies, monoclonal, humanized
Lymphoma, T-Cell, cutaneous
Sézary syndrome
Treatment outcome
topic Antibodies, monoclonal, humanized
Lymphoma, T-Cell, cutaneous
Sézary syndrome
Treatment outcome
description Abstract: Sézary syndrome is a primary cutaneous T-cell lymphoma characterized by the triad of erythroderma, lymphadenopathy and circulating atypical cells. The emergence of new molecular targets has enabled the development of drugs such as alemtuzumab, an anti-CD52 monoclonal antibody, which has shown promising results in the treatment of this entity. We report the case of a 70-year-old male with refractory Sézary syndrome in whom treatment with alemtuzumab achieved an 80% skin lesion clearance with complete haematologic and radiologic response. The treatment was discontinued after 4 months due to adverse effects, with the patient showing a sustained response without disease progression after 13 months of follow-up.
publishDate 2016
dc.date.none.fl_str_mv 2016-10-01
dc.type.driver.fl_str_mv info:eu-repo/semantics/report
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
format report
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0365-05962016000500642
url http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0365-05962016000500642
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv 10.1590/abd1806-4841.20164322
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv text/html
dc.publisher.none.fl_str_mv Sociedade Brasileira de Dermatologia
publisher.none.fl_str_mv Sociedade Brasileira de Dermatologia
dc.source.none.fl_str_mv Anais Brasileiros de Dermatologia v.91 n.5 2016
reponame:Anais brasileiros de dermatologia (Online)
instname:Sociedade Brasileira de Dermatologia (SBD)
instacron:SBD
instname_str Sociedade Brasileira de Dermatologia (SBD)
instacron_str SBD
institution SBD
reponame_str Anais brasileiros de dermatologia (Online)
collection Anais brasileiros de dermatologia (Online)
repository.name.fl_str_mv Anais brasileiros de dermatologia (Online) - Sociedade Brasileira de Dermatologia (SBD)
repository.mail.fl_str_mv abd@sbd.org.br||revista@sbd.org.br
_version_ 1752126421382201344

Registros relacionados